Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25846310 | 0.90 | PTGER4 (0.38) | RAB9ANPC1ALDH1A1GAAKMT2A | |
| SCHEMBL25845606 | 0.77 | NPC1 (0.37) | RAB9ANPC1ALDH1A1GAAKDM4E | |
| SCHEMBL25845325 | 0.75 | FFAR1 (0.47) | — | |
| SCHEMBL25845336 | 0.75 | FFAR1 (0.47) | — | |
| SCHEMBL25845572 | 0.73 | PPARD (0.45) | — | |
| SCHEMBL2439272 | 0.71 | GYS1 (0.42) | ALDH1A1GAAKDM4EKMT2AMAOB | |
| SCHEMBL18111500 | 0.70 | KMT2A (0.45) | RAB9ANPC1ALDH1A1KMT2AMEN1 | |
| SCHEMBL25846319 | 0.69 | FFAR4 (0.38) | RAB9ANPC1ALDH1A1GAAKMT2A | |
| SCHEMBL25845812 | 0.69 | CD274 (0.40) | RAB9ANPC1MAOB | |
| SCHEMBL2723561 | 0.68 | ALDH1A1 (0.54) | RAB9ANPC1ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4212528-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | GPR55, GPR65, GPR4 | RAB9A 2600/4885NPC1 1707/4885ALDH1A1 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.